Latest Research And Development News

Page 12 of 115
Orivium has begun construction of a modular processing plant in Orange, NSW, to test recovery of copper from Infinity Mining’s Cangai waste. The partner-funded facility could be operational within six months, but any revenue remains conditional on feedstock access, successful processing and metal sales.
Maxwell Dee
Maxwell Dee
14 Oct 2026
Delorean Corporation has secured a non-binding $20 million financing mandate from Westpac for its NSW1 Horsley Park bioenergy project, taking identified funding to about 81% of the estimated build cost. The project still needs binding finance documents and a further $11.6 million before financial close can be reached.
Victor Sage
Victor Sage
13 Oct 2026
Prescient Therapeutics has reached the first planned review threshold in its PTX-100 Phase 2a lymphoma study, while a completed A$6.0 million raise extends funding beyond the December milestone. The review will assess safety and efficacy, but is not a study completion or a new clinical result.
Ada Torres
Ada Torres
13 Oct 2026
Mesoblast has reported a sharp commercial step-up in FY2026, with Ryoncil generating US$115.2 million in net sales and total revenue reaching US$120.3 million. The company has also completed treatment in its 350-patient back-pain trial and refinanced its debt, but remains loss-making and expects to need more capital beyond the next 12 months.
Ada Torres
Ada Torres
12 Oct 2026
Activeport has reported a sharp first-quarter acceleration in software revenue, alongside a leaner cost base and expanding GPU deployments. The company says $4.05 million of software project contract value was activated during the quarter, but the cash flow payoff still depends on customer usage and execution.
Sophie Babbage
Sophie Babbage
12 Oct 2026
Inghams Group Limited (ASX:ING) returned to poultry volume growth in FY26, but rising costs, a tax dispute and weaker earnings sharply reduced shareholder returns. The company enters FY27 with lower net debt, elevated leverage and a value-led turnaround strategy still to prove itself.
Victor Sage
Victor Sage
9 Oct 2026
Neurotech International has moved NTI164 into a registration-enabling Phase III autism trial, but its annual report carries a material going-concern warning. The company says post-year-end debt and equity funding should support the program through topline data, subject to execution and completion.
Ada Torres
Ada Torres
5 Oct 2026
xReality Group has identified unaudited adjustments that deepen its FY26 loss by $5.79 million and cut net assets from $14.0 million to $6.7 million. Customer revenue and cash flow are unchanged, but trading is suspended until the audit and amended accounts are completed.
Sophie Babbage
Sophie Babbage
1 Oct 2026
Stakk Limited (ASX:SKK) delivered a sharp FY2026 revenue increase and moved to audited operating profitability, but its next test is considerably larger: integrating ParaScript while servicing new debt and converting contracted revenue into cash. The company is targeting A$55.2 million of pro forma revenue and A$18.5 million of EBITDA in FY2027.
Victor Sage
Victor Sage
1 Oct 2026
Prophecy International’s revenue fell 15% and its statutory loss widened to $7.9 million in FY26, leaving the software group with $1 million in cash and negative net assets. A major restructure, new debtor finance facility and AI product launch offer a recovery plan, but the auditor has warned of material uncertainty around the company’s ability to continue as a going concern.
Victor Sage
Victor Sage
30 Sept 2026
ClearVue Technologies reported just A$108,484 of FY2026 revenue against an A$11.86 million loss, while consuming A$8.69 million in operating cash. The solar-glazing developer says certifications, international partners and an 80-project pipeline have strengthened its platform, but the next test is converting those assets into cash revenue.
Victor Sage
Victor Sage
30 Sept 2026
FBR has cut its annual loss dramatically and moved its first Mantis welding robot into commissioning, but year-end cash of just A$27,814 leaves the company dependent on fundraising, tax funding and successful delivery. Its audited accounts flag a material uncertainty over whether the robotics developer can continue as a going concern.
Victor Sage
Victor Sage
30 Sept 2026

Browse the archive

Full archive